Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- tear break up time test and shirmer test
研究概览
简要总结
Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment.
详细描述
Aromatase inhibitors (AI) therapy is an important treatment for estrogen receptor-positive breast cancer (BC). This work evaluated the eye anterior segment changes in estrogen-dependent BC after hormonal treatment.
This cross-sectional study was conducted on female patients aged ≥18 who received treatment for BC. Patients were evaluated by a number of tests to determine the effects on the cornea and the lacrimal system
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Females diagnosed with breast cancer
排除标准
- •uncontrolled diabetes , auto immune diseases
研究组 & 干预措施
patients with breast cancer recieving hormonal treatment
evaluation of the effect of hormonal treatment on the cornea
干预措施: Hormonal treatment (Drug)
结局指标
主要结局
tear break up time test and shirmer test
时间窗: 6 months
these tests done before starting treatment and in follow up after recieving treatment to evaluate the lacrimal function and dry eye
次要结局
- Corneal thickness and endothelium hexagonality(6 months)